Efficacy of a Therapeutic Treatment Trial in Angelman Syndrome View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2006-2010

ABSTRACT

Angelman syndrome (AS) is a complex genetic disorder that affects the nervous system. The purpose of this study is to determine the effectiveness of certain dietary supplements in treating the symptoms of AS. Detailed Description AS is a neurologic disorder that may cause developmental delay, mental retardation, severe speech impairment, seizures, small head size, and problems with movement and balance in young children. AS is caused by a missing or incomplete chromosome 15 that is inherited from the mother. Diagnosis of AS is usually made between three and seven years of age, when the characteristic behaviors and features of the disease become most evident. Prior to AS diagnosis, the symptoms may be mistaken for cerebral palsy or autism. Physical, occupational, and speech therapy, communication skills development, and behavior modification help to improve the quality of life of these children, but other treatments are needed. In a previous study, decreased DNA methylation, which is a type of chemical change in DNA, was observed in an individual with AS; this condition may be a primary cause of AS. It is hypothesized that promoting increased DNA methylation might reduce the severity of AS symptoms. Betaine, creatine, Metafolin, and vitamin B12 are compounds normally found in the body that are involved in the DNA methylation pathway. Increasing the concentrations of these compounds in the body may enhance DNA methylation. This study will evaluate the efficacy of four dietary supplements in treating the symptoms of AS. This study will last 12 months. Study visits will occur at study entry and Month 12. A selected group of participants, those who meet the diagnostic criteria for autism, will also be evaluated at Month 6. At study visits, participants will undergo an electroencephalogram (EEG). Medical history, physical exam, neurological exams, and developmental assessments will also be performed. Urine and blood collection, including tests to determine the blood levels of the dietary supplements, will occur at study entry and Months 6 and 12. Participants will receive two daily doses of Metafolin, betaine, and creatine, and one daily dose of vitamin B12 for the duration of the study. Parents will be asked to complete a questionnaire at each visit to report their child's behavior while taking the dietary supplements. Parents will also be contacted by phone periodically to assess changes and/or progress in their children. More... »

URL

https://clinicaltrials.gov/show/NCT00348933

Related SciGraph Publications

  • 1997-01. UBE3A/E6-AP mutations cause Angelman syndrome in NATURE GENETICS
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "description": "Angelman syndrome (AS) is a complex genetic disorder that affects the nervous system. The purpose of this study is to determine the effectiveness of certain dietary supplements in treating the symptoms of AS.\n\nDetailed Description\nAS is a neurologic disorder that may cause developmental delay, mental retardation, severe speech impairment, seizures, small head size, and problems with movement and balance in young children. AS is caused by a missing or incomplete chromosome 15 that is inherited from the mother. Diagnosis of AS is usually made between three and seven years of age, when the characteristic behaviors and features of the disease become most evident. Prior to AS diagnosis, the symptoms may be mistaken for cerebral palsy or autism. Physical, occupational, and speech therapy, communication skills development, and behavior modification help to improve the quality of life of these children, but other treatments are needed. In a previous study, decreased DNA methylation, which is a type of chemical change in DNA, was observed in an individual with AS; this condition may be a primary cause of AS. It is hypothesized that promoting increased DNA methylation might reduce the severity of AS symptoms. Betaine, creatine, Metafolin, and vitamin B12 are compounds normally found in the body that are involved in the DNA methylation pathway. Increasing the concentrations of these compounds in the body may enhance DNA methylation. This study will evaluate the efficacy of four dietary supplements in treating the symptoms of AS. This study will last 12 months. Study visits will occur at study entry and Month 12. A selected group of participants, those who meet the diagnostic criteria for autism, will also be evaluated at Month 6. At study visits, participants will undergo an electroencephalogram (EEG). Medical history, physical exam, neurological exams, and developmental assessments will also be performed. Urine and blood collection, including tests to determine the blood levels of the dietary supplements, will occur at study entry and Months 6 and 12. Participants will receive two daily doses of Metafolin, betaine, and creatine, and one daily dose of vitamin B12 for the duration of the study. Parents will be asked to complete a questionnaire at each visit to report their child's behavior while taking the dietary supplements. Parents will also be contacted by phone periodically to assess changes and/or progress in their children.", 
        "endDate": "2010-02-01T00:00:00Z", 
        "id": "sg:clinicaltrial.NCT00348933", 
        "keywords": [
          "efficacy", 
          "therapeutic treatment", 
          "Angelman syndrome", 
          "complex genetic disorder", 
          "nervous system", 
          "effectiveness", 
          "dietary supplement", 
          "symptom", 
          "Nervous System Disease", 
          "developmental delay", 
          "Intellectual Disability", 
          "speech impairment", 
          "seizure", 
          "head size", 
          "movement", 
          "balance", 
          "young child", 
          "chromosome", 
          "mother", 
          "diagnosis", 
          "age", 
          "characteristic behavior", 
          "feature", 
          "disease", 
          "cerebral palsy", 
          "Autistic Disorder", 
          "speech therapy", 
          "communication skill", 
          "behavior therapy", 
          "life", 
          "child", 
          "previous study", 
          "DNA methylation", 
          "chemical change", 
          "DNA", 
          "condition", 
          "severity", 
          "betaine", 
          "creatine", 
          "Vitamin B 12", 
          "compound", 
          "body", 
          "Attention", 
          "study visit", 
          "study entry", 
          "selected group", 
          "diagnostic criterion", 
          "Electroencephalography", 
          "medical history", 
          "physical exam", 
          "neurological exam", 
          "developmental assessment", 
          "urine", 
          "blood collection", 
          "blood level", 
          "dose", 
          "duration", 
          "parent", 
          "questionnaire", 
          "visit", 
          "behavior", 
          "phone", 
          "progress"
        ], 
        "name": "Efficacy of a Therapeutic Treatment Trial in Angelman Syndrome", 
        "sameAs": [
          "https://app.dimensions.ai/details/clinical_trial/NCT00348933"
        ], 
        "sdDataset": "clinical_trials", 
        "sdDatePublished": "2019-03-07T15:22", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "file:///pack/app/us_ct_data_00003.json", 
        "sponsor": [
          {
            "id": "https://www.grid.ac/institutes/grid.286440.c", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418307.9", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.2515.3", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.39382.33", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.266100.3", 
            "type": "Organization"
          }
        ], 
        "startDate": "2006-07-01T00:00:00Z", 
        "subjectOf": [
          {
            "id": "sg:pub.10.1038/ng0197-70", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012945311", 
              "https://doi.org/10.1038/ng0197-70"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/ajmg.1316", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013251537"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/ajmg.a.31074", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033344464"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/ajmg.a.34297", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047840393"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "type": "MedicalStudy", 
        "url": "https://clinicaltrials.gov/show/NCT00348933"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00348933'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00348933'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00348933'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00348933'


     

    This table displays all metadata directly associated to this object as RDF triples.

    103 TRIPLES      16 PREDICATES      86 URIs      72 LITERALS      1 BLANK NODES

    Subject Predicate Object
    1 sg:clinicaltrial.NCT00348933 schema:about anzsrc-for:3053
    2 schema:description Angelman syndrome (AS) is a complex genetic disorder that affects the nervous system. The purpose of this study is to determine the effectiveness of certain dietary supplements in treating the symptoms of AS. Detailed Description AS is a neurologic disorder that may cause developmental delay, mental retardation, severe speech impairment, seizures, small head size, and problems with movement and balance in young children. AS is caused by a missing or incomplete chromosome 15 that is inherited from the mother. Diagnosis of AS is usually made between three and seven years of age, when the characteristic behaviors and features of the disease become most evident. Prior to AS diagnosis, the symptoms may be mistaken for cerebral palsy or autism. Physical, occupational, and speech therapy, communication skills development, and behavior modification help to improve the quality of life of these children, but other treatments are needed. In a previous study, decreased DNA methylation, which is a type of chemical change in DNA, was observed in an individual with AS; this condition may be a primary cause of AS. It is hypothesized that promoting increased DNA methylation might reduce the severity of AS symptoms. Betaine, creatine, Metafolin, and vitamin B12 are compounds normally found in the body that are involved in the DNA methylation pathway. Increasing the concentrations of these compounds in the body may enhance DNA methylation. This study will evaluate the efficacy of four dietary supplements in treating the symptoms of AS. This study will last 12 months. Study visits will occur at study entry and Month 12. A selected group of participants, those who meet the diagnostic criteria for autism, will also be evaluated at Month 6. At study visits, participants will undergo an electroencephalogram (EEG). Medical history, physical exam, neurological exams, and developmental assessments will also be performed. Urine and blood collection, including tests to determine the blood levels of the dietary supplements, will occur at study entry and Months 6 and 12. Participants will receive two daily doses of Metafolin, betaine, and creatine, and one daily dose of vitamin B12 for the duration of the study. Parents will be asked to complete a questionnaire at each visit to report their child's behavior while taking the dietary supplements. Parents will also be contacted by phone periodically to assess changes and/or progress in their children.
    3 schema:endDate 2010-02-01T00:00:00Z
    4 schema:keywords Angelman syndrome
    5 Attention
    6 Autistic Disorder
    7 DNA
    8 DNA methylation
    9 Electroencephalography
    10 Intellectual Disability
    11 Nervous System Disease
    12 Vitamin B 12
    13 age
    14 balance
    15 behavior
    16 behavior therapy
    17 betaine
    18 blood collection
    19 blood level
    20 body
    21 cerebral palsy
    22 characteristic behavior
    23 chemical change
    24 child
    25 chromosome
    26 communication skill
    27 complex genetic disorder
    28 compound
    29 condition
    30 creatine
    31 developmental assessment
    32 developmental delay
    33 diagnosis
    34 diagnostic criterion
    35 dietary supplement
    36 disease
    37 dose
    38 duration
    39 effectiveness
    40 efficacy
    41 feature
    42 head size
    43 life
    44 medical history
    45 mother
    46 movement
    47 nervous system
    48 neurological exam
    49 parent
    50 phone
    51 physical exam
    52 previous study
    53 progress
    54 questionnaire
    55 seizure
    56 selected group
    57 severity
    58 speech impairment
    59 speech therapy
    60 study entry
    61 study visit
    62 symptom
    63 therapeutic treatment
    64 urine
    65 visit
    66 young child
    67 schema:name Efficacy of a Therapeutic Treatment Trial in Angelman Syndrome
    68 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00348933
    69 schema:sdDatePublished 2019-03-07T15:22
    70 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    71 schema:sdPublisher N0252cda031074ce5b63be113a28f2c79
    72 schema:sponsor https://www.grid.ac/institutes/grid.2515.3
    73 https://www.grid.ac/institutes/grid.266100.3
    74 https://www.grid.ac/institutes/grid.286440.c
    75 https://www.grid.ac/institutes/grid.39382.33
    76 https://www.grid.ac/institutes/grid.418307.9
    77 schema:startDate 2006-07-01T00:00:00Z
    78 schema:subjectOf sg:pub.10.1038/ng0197-70
    79 https://doi.org/10.1002/ajmg.1316
    80 https://doi.org/10.1002/ajmg.a.31074
    81 https://doi.org/10.1002/ajmg.a.34297
    82 schema:url https://clinicaltrials.gov/show/NCT00348933
    83 sgo:license sg:explorer/license/
    84 sgo:sdDataset clinical_trials
    85 rdf:type schema:MedicalStudy
    86 N0252cda031074ce5b63be113a28f2c79 schema:name Springer Nature - SN SciGraph project
    87 rdf:type schema:Organization
    88 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
    89 rdf:type schema:DefinedTerm
    90 sg:pub.10.1038/ng0197-70 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012945311
    91 https://doi.org/10.1038/ng0197-70
    92 rdf:type schema:CreativeWork
    93 https://doi.org/10.1002/ajmg.1316 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013251537
    94 rdf:type schema:CreativeWork
    95 https://doi.org/10.1002/ajmg.a.31074 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033344464
    96 rdf:type schema:CreativeWork
    97 https://doi.org/10.1002/ajmg.a.34297 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047840393
    98 rdf:type schema:CreativeWork
    99 https://www.grid.ac/institutes/grid.2515.3 schema:Organization
    100 https://www.grid.ac/institutes/grid.266100.3 schema:Organization
    101 https://www.grid.ac/institutes/grid.286440.c schema:Organization
    102 https://www.grid.ac/institutes/grid.39382.33 schema:Organization
    103 https://www.grid.ac/institutes/grid.418307.9 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...